< Back to latest news & events

News

EPO continues oral proceedings by videoconference in examination and opposition during pendency of referral G 1/21

March 2021

The EPO Boards of Appeal took the decision that from the start of 2021, all Boards of Appeal oral proceedings could be held by videoconference, even if the parties to the proceedings were not in agreement (ostensibly aping the position before Opposition and Examining Divisions).

This decision has been divisive since many believe that holding proceedings by video conference does not give either appellants or respondents the best chance of presenting their case.

On 12 March 2021, Technical Board of Appeal 3.5.02 in appeal case T1807/15 made a referral to the Enlarged Board of Appeal seeking to clarify whether, in view of Article 116(1) EPC, oral proceedings may be conducted by videoconference (VICO) without all parties’ consent. The referral concerns appeal proceedings, but also extends to oral proceedings by VICO before examining and opposition divisions.

The following question was referred to the Enlarged Board of Appeal (G 1/21):

“Is the conduct of oral proceedings in the form of a videoconference compatible with the right to oral proceedings as enshrined in Article 116(1) EPC if not all of the parties to the proceedings have given their consent to the conduct of oral proceedings in the form of a videoconference?”

The Enlarged Board of Appeal will consider the referral on 28 May 2021.

The EPO has today stated that during pendency of the referral, oral proceedings before examining and opposition divisions will continue to be held by VICO as under current practice – that is, without requiring explicit agreement of the parties.  The statement from the EPO does not explicitly mention oral proceedings before the Boards of Appeal however.  It is therefore arguable that the EPO would consider a request for a stay of proceeding in light of the pending referral G 1/12.

This article was prepared by HGF Partner Dr Chris Moore. If you would like further advice on this or any other matter, please contact Chris. Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

Polymorphs: Clearing the Inventive Step Hurdle at the European Patent Office (EPO)

Polymorphic forms of active pharmaceutical ingredients (APIs) can represent commercially valuable compound subject matter and can be critical to providing necessary drug product characteristics and performance. However, patenting polymorphs is …

Read article

IQPC Global US Exchange

HGF are proud ‘Silver Plus’ sponsors of the IQPC Global US Exchange, at the Austin Marriot South, Texas. The IQPC Global US Exchange will be held at the Austin Marriot …

Read article

Update on the Precision Breeding Act 2023: details emerge of the new simplified regulatory pathway for gene edited plant and animal derived food and feed products

The Genetic Technology (Precision Breeding) Act 2023 could come into force as early as spring 2025. It empowers the Food Standards Agency (FSA) to create a new simplified regulatory pathway …

Read article

Court of Appeal Decision Upholds Invalidity of Patent Due to Amendment Identifying Embodiment as Outside the Scope of the Claims

In a case that highlights the challenges arising due to post-grant amendments, and in particular interpretation of the claims in view of the description, the Court of Appeal in Ensygnia …

Read article

UPC Court of Appeal clarifies approach for interpreting claims with “obvious” errors

Alexion Pharmaceuticals, Inc. v Samsung Bioepis NL B.V. [UPC_CoA_402/2024] –Court of Appeal of the UPC (Grabinski, Blok, Gougé, Enderlin, Hedberg) – 20 December 2024 Alexion Pharmaceuticals, Inc. v Amgen Technology …

Read article

IP Ingredients: Winter Case Law Review 2024

As the nights draw in and the frenzy to finish everything off before the holiday season reaches its peak, it’s time to take a break, grab your favourite hot beverage …

Read article